| P50 | author | Jeffrey L. Neul | Q55459508 |
| | Walter E Kaufmann | Q92960213 |
| | Daniel G Glaze | Q99546359 |
| | Alan K. Percy | Q107392636 |
| P2093 | author name string | Wei Hou | |
| | Kathleen J Motil | |
| | Steven A Skinner | |
| | Jane B Lane | |
| | Anne Berg | |
| | Daniel C Tarquinio | |
| P2860 | cites work | Rett syndrome: revised diagnostic criteria and nomenclature | Q24596295 |
| | Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) | Q28243974 |
| | Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy | Q28267579 |
| | FXYD1, a modulator of Na,K-ATPase activity, facilitates female sexual development by maintaining gonadotrophin-releasing hormone neuronal excitability | Q28572180 |
| | CDC growth charts: United States | Q29615833 |
| | Loss of MeCP2 in Parvalbumin-and Somatostatin-Expressing Neurons in Mice Leads to Distinct Rett Syndrome-like Phenotypes | Q30369619 |
| | Epilepsy and the natural history of Rett syndrome. | Q33720770 |
| | Twenty years of surveillance in Rett syndrome: what does this tell us? | Q33833275 |
| | What you seize is what you get: do we yet understand epilepsy in rett syndrome? | Q34306205 |
| | Seizures in Rett syndrome: an overview from a one-year calendar study | Q34455774 |
| | Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice | Q34989741 |
| | Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome | Q35492500 |
| | Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis | Q35584759 |
| | Clinical severity and quality of life in children and adolescents with Rett syndrome | Q35599532 |
| | Ketone bodies mediate antiseizure effects through mitochondrial permeability transition | Q35779437 |
| | The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders. | Q36173598 |
| | Growth failure and outcome in Rett syndrome: specific growth references | Q36310174 |
| | Vitamin D deficiency is prevalent in girls and women with Rett syndrome | Q36800831 |
| | Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus | Q37223275 |
| | Assessment and management of nutrition and growth in Rett syndrome | Q37529852 |
| | Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures | Q37578480 |
| | Prognosis of intractable epilepsy: is long-term seizure freedom possible with medical management? | Q37860979 |
| | The course of childhood-onset epilepsy over the first two decades: a prospective, longitudinal study | Q38272239 |
| | Aging in Rett syndrome: a longitudinal study | Q39516959 |
| | Antiepileptic drugs in Rett Syndrome | Q41151966 |
| | Epilepsy in Rett syndrome--lessons from the Rett networked database | Q41193372 |
| | Valproate and risk of fracture in Rett syndrome | Q43054627 |
| | Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome | Q43241995 |
| | Lamotrigine in two cases of Rett syndrome | Q43620097 |
| | Effect of topiramate on seizures and respiratory dysrhythmia in Rett syndrome | Q45191353 |
| | Rett syndrome: a mitochondrial disease? | Q45758910 |
| | Using a large international sample to investigate epilepsy in Rett syndrome. | Q45957439 |
| | Therapeutic effects of a ketogenic diet in Rett syndrome | Q46156332 |
| | Reduced seizure threshold and altered network oscillatory properties in a mouse model of Rett syndrome | Q46556567 |
| | Gastrostomy placement improves height and weight gain in girls with Rett syndrome | Q47180189 |
| | British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood | Q47294166 |
| | Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome | Q48454183 |
| | The increase in body weight induced by lack of methyl CpG binding protein-2 is associated with altered leptin signalling in the hypothalamus | Q48675850 |
| | Impaired mitochondrial energy production: the basis of pharmacoresistance in epilepsy | Q49077699 |
| | Epilepsy in Rett syndrome: association between phenotype and genotype, and implications for practice. | Q51860709 |
| | Epilepsy in a representative series of Rett syndrome. | Q51969154 |
| | Guidelines for Epidemiologic Studies on Epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy | Q53980075 |
| | Medical care of adolescents and women with Rett syndrome: An Italian study | Q59222752 |
| | Rett syndrome and mitochondrial enzyme deficiencies | Q68239232 |
| | Rett syndrome: characterization of seizures versus non-seizures | Q74813144 |
| | An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001 | Q78369107 |
| | Neurophysiology of Rett syndrome | Q81353270 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Rett syndrome | Q917357 |
| P304 | page(s) | 306-318 | |
| P577 | publication date | 2016-12-21 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Longitudinal course of epilepsy in Rett syndrome and related disorders | |
| P478 | volume | 140 | |